Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy

Toyoaki Hida, Kazuhiko Nakagawa, Takashi Seto, Miyako Satouchi, Makoto Nishio, Katsuyuki Hotta, Toshiaki Takahashi, Yuichiro Ohe, Koji Takeda, Masahiro Tatsuno, Takashi Asakawa, Tadashi Shimada, Tomohiro Tanaka, Tomohide Tamura

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We report pharmacokinetics, efficacy and safety data for a new 150-mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastatic ALK+ disease, ALK inhibitor-naïve and -pretreated [including crizotinib refractory]) were randomized 1:1 to receive one of two sequences of alectinib 300 mg twice daily (comprising different schedules of 20/40-mg and 150-mg capsules) until investigator-determined lack of clinical benefit. Co-primary endpoints were: bioequivalence of alectinib 20/40 mg vs 150 mg; food effect with 150 mg; and safety. Thirty-five patients were enrolled; median treatment duration was 13.1 months (range 1.1−15.0). Under fasting conditions, exposure of the two formulations was similar; mean AUClast ± standard deviation 3230 ± 914 h·ng/mL vs 3710 ± 1040 h·ng/mL, respectively, for 150-mg vs 20/40-mg capsules. Food effect with 150 mg alectinib was negligible. Treatment-related adverse events in >20% of patients were constipation (31.4%), dysgeusia (25.7%), and decreased white blood cell and neutrophil count (22.9% each). No treatment-related grade 4/5 events occurred. Median time to response was 1.2 months (95% CI 1.1−2.1). For the full analysis set (n = 35) and crizotinib-failure subpopulations (n = 23), the overall response rate was 70.0% (95% CI 50.6−85.3) and 65.0% (95% CI 40.8−84.6), and median progression-free survival was 13.9 months (95% CI 11.1−not reached) and 12.9 months (95% CI 3.9−not reached), respectively. The 150-mg capsule had a similar exposure profile to 20/40-mg capsules. Alectinib demonstrated promising efficacy and was well tolerated.

Original languageEnglish
Pages (from-to)1642-1646
Number of pages5
JournalCancer Science
Volume107
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Capsules
Dysgeusia
Therapeutics
Safety
Food
Therapeutic Equivalency
Constipation
Leukocyte Count
Disease-Free Survival
Fasting
Appointments and Schedules
Neutrophils
Pharmacokinetics
Research Personnel
CH5424802
crizotinib

Keywords

  • Alectinib
  • anaplastic lymphoma kinase
  • bioequivalence
  • Japanese
  • non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy. / Hida, Toyoaki; Nakagawa, Kazuhiko; Seto, Takashi; Satouchi, Miyako; Nishio, Makoto; Hotta, Katsuyuki; Takahashi, Toshiaki; Ohe, Yuichiro; Takeda, Koji; Tatsuno, Masahiro; Asakawa, Takashi; Shimada, Tadashi; Tanaka, Tomohiro; Tamura, Tomohide.

In: Cancer Science, Vol. 107, No. 11, 01.11.2016, p. 1642-1646.

Research output: Contribution to journalArticle

Hida, T, Nakagawa, K, Seto, T, Satouchi, M, Nishio, M, Hotta, K, Takahashi, T, Ohe, Y, Takeda, K, Tatsuno, M, Asakawa, T, Shimada, T, Tanaka, T & Tamura, T 2016, 'Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy', Cancer Science, vol. 107, no. 11, pp. 1642-1646. https://doi.org/10.1111/cas.13066
Hida, Toyoaki ; Nakagawa, Kazuhiko ; Seto, Takashi ; Satouchi, Miyako ; Nishio, Makoto ; Hotta, Katsuyuki ; Takahashi, Toshiaki ; Ohe, Yuichiro ; Takeda, Koji ; Tatsuno, Masahiro ; Asakawa, Takashi ; Shimada, Tadashi ; Tanaka, Tomohiro ; Tamura, Tomohide. / Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy. In: Cancer Science. 2016 ; Vol. 107, No. 11. pp. 1642-1646.
@article{887d71f861db47519590252e4a8625e2,
title = "Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy",
abstract = "We report pharmacokinetics, efficacy and safety data for a new 150-mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastatic ALK+ disease, ALK inhibitor-na{\"i}ve and -pretreated [including crizotinib refractory]) were randomized 1:1 to receive one of two sequences of alectinib 300 mg twice daily (comprising different schedules of 20/40-mg and 150-mg capsules) until investigator-determined lack of clinical benefit. Co-primary endpoints were: bioequivalence of alectinib 20/40 mg vs 150 mg; food effect with 150 mg; and safety. Thirty-five patients were enrolled; median treatment duration was 13.1 months (range 1.1−15.0). Under fasting conditions, exposure of the two formulations was similar; mean AUClast ± standard deviation 3230 ± 914 h·ng/mL vs 3710 ± 1040 h·ng/mL, respectively, for 150-mg vs 20/40-mg capsules. Food effect with 150 mg alectinib was negligible. Treatment-related adverse events in >20{\%} of patients were constipation (31.4{\%}), dysgeusia (25.7{\%}), and decreased white blood cell and neutrophil count (22.9{\%} each). No treatment-related grade 4/5 events occurred. Median time to response was 1.2 months (95{\%} CI 1.1−2.1). For the full analysis set (n = 35) and crizotinib-failure subpopulations (n = 23), the overall response rate was 70.0{\%} (95{\%} CI 50.6−85.3) and 65.0{\%} (95{\%} CI 40.8−84.6), and median progression-free survival was 13.9 months (95{\%} CI 11.1−not reached) and 12.9 months (95{\%} CI 3.9−not reached), respectively. The 150-mg capsule had a similar exposure profile to 20/40-mg capsules. Alectinib demonstrated promising efficacy and was well tolerated.",
keywords = "Alectinib, anaplastic lymphoma kinase, bioequivalence, Japanese, non-small-cell lung cancer",
author = "Toyoaki Hida and Kazuhiko Nakagawa and Takashi Seto and Miyako Satouchi and Makoto Nishio and Katsuyuki Hotta and Toshiaki Takahashi and Yuichiro Ohe and Koji Takeda and Masahiro Tatsuno and Takashi Asakawa and Tadashi Shimada and Tomohiro Tanaka and Tomohide Tamura",
year = "2016",
month = "11",
day = "1",
doi = "10.1111/cas.13066",
language = "English",
volume = "107",
pages = "1642--1646",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy

AU - Hida, Toyoaki

AU - Nakagawa, Kazuhiko

AU - Seto, Takashi

AU - Satouchi, Miyako

AU - Nishio, Makoto

AU - Hotta, Katsuyuki

AU - Takahashi, Toshiaki

AU - Ohe, Yuichiro

AU - Takeda, Koji

AU - Tatsuno, Masahiro

AU - Asakawa, Takashi

AU - Shimada, Tadashi

AU - Tanaka, Tomohiro

AU - Tamura, Tomohide

PY - 2016/11/1

Y1 - 2016/11/1

N2 - We report pharmacokinetics, efficacy and safety data for a new 150-mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastatic ALK+ disease, ALK inhibitor-naïve and -pretreated [including crizotinib refractory]) were randomized 1:1 to receive one of two sequences of alectinib 300 mg twice daily (comprising different schedules of 20/40-mg and 150-mg capsules) until investigator-determined lack of clinical benefit. Co-primary endpoints were: bioequivalence of alectinib 20/40 mg vs 150 mg; food effect with 150 mg; and safety. Thirty-five patients were enrolled; median treatment duration was 13.1 months (range 1.1−15.0). Under fasting conditions, exposure of the two formulations was similar; mean AUClast ± standard deviation 3230 ± 914 h·ng/mL vs 3710 ± 1040 h·ng/mL, respectively, for 150-mg vs 20/40-mg capsules. Food effect with 150 mg alectinib was negligible. Treatment-related adverse events in >20% of patients were constipation (31.4%), dysgeusia (25.7%), and decreased white blood cell and neutrophil count (22.9% each). No treatment-related grade 4/5 events occurred. Median time to response was 1.2 months (95% CI 1.1−2.1). For the full analysis set (n = 35) and crizotinib-failure subpopulations (n = 23), the overall response rate was 70.0% (95% CI 50.6−85.3) and 65.0% (95% CI 40.8−84.6), and median progression-free survival was 13.9 months (95% CI 11.1−not reached) and 12.9 months (95% CI 3.9−not reached), respectively. The 150-mg capsule had a similar exposure profile to 20/40-mg capsules. Alectinib demonstrated promising efficacy and was well tolerated.

AB - We report pharmacokinetics, efficacy and safety data for a new 150-mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastatic ALK+ disease, ALK inhibitor-naïve and -pretreated [including crizotinib refractory]) were randomized 1:1 to receive one of two sequences of alectinib 300 mg twice daily (comprising different schedules of 20/40-mg and 150-mg capsules) until investigator-determined lack of clinical benefit. Co-primary endpoints were: bioequivalence of alectinib 20/40 mg vs 150 mg; food effect with 150 mg; and safety. Thirty-five patients were enrolled; median treatment duration was 13.1 months (range 1.1−15.0). Under fasting conditions, exposure of the two formulations was similar; mean AUClast ± standard deviation 3230 ± 914 h·ng/mL vs 3710 ± 1040 h·ng/mL, respectively, for 150-mg vs 20/40-mg capsules. Food effect with 150 mg alectinib was negligible. Treatment-related adverse events in >20% of patients were constipation (31.4%), dysgeusia (25.7%), and decreased white blood cell and neutrophil count (22.9% each). No treatment-related grade 4/5 events occurred. Median time to response was 1.2 months (95% CI 1.1−2.1). For the full analysis set (n = 35) and crizotinib-failure subpopulations (n = 23), the overall response rate was 70.0% (95% CI 50.6−85.3) and 65.0% (95% CI 40.8−84.6), and median progression-free survival was 13.9 months (95% CI 11.1−not reached) and 12.9 months (95% CI 3.9−not reached), respectively. The 150-mg capsule had a similar exposure profile to 20/40-mg capsules. Alectinib demonstrated promising efficacy and was well tolerated.

KW - Alectinib

KW - anaplastic lymphoma kinase

KW - bioequivalence

KW - Japanese

KW - non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84997610867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997610867&partnerID=8YFLogxK

U2 - 10.1111/cas.13066

DO - 10.1111/cas.13066

M3 - Article

VL - 107

SP - 1642

EP - 1646

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -